王人灵 唐冬艳 叶大胜

[摘要]目的探究貝伐珠单抗靶向治疗联合 FOLFIRILOX 化疗方案治疗晚期结直肠癌的效果及对患者免疫功能的影响。方法选取2016年1月至2020年12月开平市中心医院行晚期结直肠癌治疗的80例患者，基于不同治疗方法分为对照组与观察组，每组各40例。对照组予单纯 FOLFIRILOX 化疗，观察组则予以贝伐珠单抗靶向治疗联合 FOLFIRILOX 化疗。分析比较两组治疗后血清中免疫功能及肿瘤标志物指标、治疗效果及不良反应发生情况。结果观察组血清中3项免疫功能指标及3项肿瘤标志物指标均显著低于对照组（ P <0.05）;观察组总有效率（62.50%）及控制率（90.00%）均显著高于对照组（37.50%、62.50%）（ P <0.05）;观察组不良反应总发生率（17.50%）稍高于对照组（12.50%），但差异无统计学意义（ P >0.05）。结论贝伐珠单抗靶向治疗联合 FOLFIRILOX 化疗方案治疗晚期结直肠癌能够有效降低血清中肿瘤标志物浓度，有效提高治疗有效率及疾病控制率，且不增加患者不良反应。

[关键词]结肠癌;晚期;贝伐珠单抗;靶向; FOLFIRILOX 化疗方案;免疫功能

[中图分类号] R735.34  [文献标识码] A   [文章编号]2095-0616（2021）24-0196-04

Effect of targeted therapy with bevacizumab combined with FOLFIRILOX chemotherapy in the treatment of advanced colorectal cancer and its influence on patients' immune function

WANG  Renling    TANG  Dongyan    YE  Dasheng

The Second Department of Oncology， Kaiping Central Hospital， Guangdong， Kaiping 529300， China

[Abstract] Objective To explore the effect of targeted therapy with bevacizumab combined with FOLFIRILOX chemotherapy in the treatment of advanced colorectal cancer （ACC） and its influence on patients' immune function. Methods A total of Eighty patients with ACC treated in Kaiping Central Hospital from January 2016 to December 2020 were selected. Based on different treatment methods， they were divided into the control group and the observation group， with 40 cases in each group. The control group was given FOLFIRILOX chemotherapy alone， while the observation group was given targeted therapy with bevacizumab combined with FOLFIRILOX chemotherapy. The immune function， tumor markers， therapeutic effect and adverse reactions in serum of the two groups after treatment were compared. Results Three indexes of immune function and three indexes of tumor markers in serum of observation group were significantly lower than those of control group （P <0.05）. The total effective rate and control rate in the observation group （62.50% and 90.00%） were significantly higher than those in the control group （37.50% and 62.50%）（P <0.05）. The total incidence of adverse reactions in the observation group （17.50%） was slightly higher than that in the control group （12.50%）， with no statistically significant difference （P >0 .05）. Conclusion The targeted therapy with bevacizumab combined with FOLFIRILOX chemotherapy can effectively reduce the concentration of tumor markers in serum， effectively improve the treatment efficiency and disease control rate， and do not increase the adverse reaction of patients with ACC.

[Key words] Colorectal cancer; Advanced stage; Bevacizumab; Targeted; FOLFIRILOX chemotherapy regimen; Immune function

随着社会人群生活方式及饮食结构的改变，进一步导致了人群胃肠道疾病及肿瘤的高发趋势[1-2]。结直肠癌为临床常见的恶性肿瘤，其发病率高居不下，仅次于肺癌和乳腺癌，且具有极高的病死率。结直肠癌高发于中老年，且男性病发率明显高于女性[3]。其病变部位位于肠黏膜上皮细胞，该病早期不引起明显症状而易被忽略，随着病程进展可出现局部腹痛、血便、腹泻、便秘等临床症状[4]。临床上常以5氟尿嘧啶、奥沙利铂、伊立替康作为晚期结直肠癌的治疗基础药物，虽然在提高生存期上有一定效果，但疗效仍不乐观[5]。……